Aclaris Therapeutics Stock Revenue
| ACRS Stock | USD 3.99 0.19 5.00% |
Aclaris Therapeutics fundamentals help investors to digest information that contributes to Aclaris Therapeutics' financial success or failures. It also enables traders to predict the movement of Aclaris Stock. The fundamental analysis module provides a way to measure Aclaris Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aclaris Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 31.2 M | 32.8 M |
Aclaris | Revenue |
Aclaris Therapeutics Company Revenue Analysis
Aclaris Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Aclaris Therapeutics Revenue | 31.25 M |
Most of Aclaris Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aclaris Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Aclaris
Projected quarterly revenue analysis of Aclaris Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Aclaris Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Aclaris Therapeutics' stock price.
Aclaris Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Aclaris Therapeutics is extremely important. It helps to project a fair market value of Aclaris Stock properly, considering its historical fundamentals such as Revenue. Since Aclaris Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aclaris Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aclaris Therapeutics' interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Aclaris Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Aclaris Therapeutics reported 31.25 M of revenue. This is 99.59% lower than that of the Pharmaceuticals sector and 98.42% lower than that of the Health Care industry. The revenue for all United States stocks is 99.67% higher than that of the company.
Aclaris Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aclaris Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aclaris Therapeutics could also be used in its relative valuation, which is a method of valuing Aclaris Therapeutics by comparing valuation metrics of similar companies.Aclaris Therapeutics is currently under evaluation in revenue category among its peers.
Aclaris Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aclaris Therapeutics from analyzing Aclaris Therapeutics' financial statements. These drivers represent accounts that assess Aclaris Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aclaris Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 78.1M | 275.2M | 824.9M | 73.3M | 84.3M | 80.1M | |
| Enterprise Value | 42.8M | 232.4M | 798.2M | 33.8M | 38.9M | 37.0M |
Aclaris Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aclaris Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aclaris Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aclaris Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aclaris Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aclaris Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aclaris Therapeutics' value.| Shares | Qube Research & Technologies | 2024-06-30 | 940.8 K | Deutsche Bank Ag | 2024-06-30 | 923.3 K | Goldman Sachs Group Inc | 2024-06-30 | 916.6 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 915.5 K | Two Sigma Investments Llc | 2024-09-30 | 907.9 K | Geode Capital Management, Llc | 2024-09-30 | 846.4 K | Samsara Biocapital, Llc | 2024-09-30 | 696.2 K | Acuitas Investments, Llc | 2024-09-30 | 578.1 K | Palo Alto Investors, Llc | 2024-09-30 | 569.8 K | Bml Capital Management Llc | 2024-09-30 | 14.2 M | Vanguard Group Inc | 2024-09-30 | 4.7 M |
Aclaris Fundamentals
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (1.37) % | ||||
| Operating Margin | (2.23) % | ||||
| Current Valuation | 152.76 M | ||||
| Shares Outstanding | 71.43 M | ||||
| Shares Owned By Insiders | 3.59 % | ||||
| Shares Owned By Institutions | 84.67 % | ||||
| Number Of Shares Shorted | 2.41 M | ||||
| Price To Earning | (12.14) X | ||||
| Price To Book | 2.09 X | ||||
| Price To Sales | 10.02 X | ||||
| Revenue | 31.25 M | ||||
| Gross Profit | (60.02 M) | ||||
| EBITDA | (117.56 M) | ||||
| Net Income | (88.48 M) | ||||
| Cash And Equivalents | 248.6 M | ||||
| Cash Per Share | 3.73 X | ||||
| Total Debt | 426 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.99 X | ||||
| Book Value Per Share | 1.82 X | ||||
| Cash Flow From Operations | (78.33 M) | ||||
| Short Ratio | 3.56 X | ||||
| Earnings Per Share | (0.52) X | ||||
| Price To Earnings To Growth | (0.13) X | ||||
| Target Price | 7.6 | ||||
| Number Of Employees | 86 | ||||
| Beta | 0.12 | ||||
| Market Capitalization | 271.44 M | ||||
| Total Asset | 197.41 M | ||||
| Retained Earnings | (770.8 M) | ||||
| Working Capital | 97.9 M | ||||
| Current Asset | 86.52 M | ||||
| Current Liabilities | 1.55 M | ||||
| Net Asset | 197.41 M |
About Aclaris Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aclaris Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aclaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aclaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.